Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

mark Jephcott

  • Home
  • Author: mark Jephcott

VIRAL LOAD and COVID-19: how concerned should we be? asks GlobalData

Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData, a leading data and analytics company, offers his view on this phenomena and how concerned we should be about it; “A recent study from China supports a higher viral […]
Read more

Novartis’ Zolgensma expected to generate global sales of $2.5bn by 2025 with new data set to bolster the drug’s uptake, says GlobalData

Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global sales of $2.5bn by 2025 and lead the spinal muscular atrophy (SMA) market, says GlobalData, a leading data and analytics company. The data showed significant therapeutic benefit in patients with […]
Read more

An estimated 330m people, 15% of the 9MM population, face risk of severe COVID-19, says GlobalData

Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 […]
Read more

Bristol-Myers Squibb’s plans to divest Celgene’s Otezla after $74Bn merger deal shows the company’s confidence in their psoriasis pipeline TYK2 drug

Following the recent news that Bristol-Myers Squibb (BMS) will divest Celgene’s Otezla to close the merger deal between the two companies; Vikesh Devlia, PhD, Immunology Analyst at GlobalData, a leading data and analytics company, offers his view: ‘‘Bristol-Myers Squibb’s Phase II pipeline drug, BMS-986165, a Tyrosine-protein Kinase 2 (TYK2) inhibitor, is yet to be approved […]
Read more
,

John Lewis becomes the latest retailer to adopt virtual and augmented reality technology as theme gains traction, says GlobalData

The adoption of virtual reality (VR) and augmented reality (AR) as a key technology theme for the future will be showcased by UK department store chain John Lewis from this week when three of its stores, Kingston, Cambridge and Horsham will utilise the technology to enable customers to visualise how the company’s interior products will […]
Read more
1 … 3 4 5